Andelyn Biosciences leverages decades of expertise in gene therapy research and manufacturing

Founded as a spin−out from Nationwide Children’s Hospital in 2020, Andelyn Biosciences leverages decades of expertise in gene therapy research and manufacturing. The company’s name is a tribute to two young gene therapy patients, Andrew and Evelyn, whose stories inspire Andelyn’s mission to make a meaningful impact on patients’ lives through advanced therapies. Andelyn Biosciences’ mission is to transform the lives of patients with genetic diseases by providing high−quality, innovative gene therapy solutions. The company envisions a future where genetic disorders are effectively treated, and patients have access to life changing therapies.